Key Points {#FPar01}
==========

Hyperlipidimia alone resulted in alterations of PSZ PK and delayed its onset of activity but had no effect on VCR PK when each drug was administered alone.Coadministration of both drugs in NL rats decreased PSZ Cl/f and increased its plasma and liver availability whereas, it increased VCR unbound fraction and tissue distribution.Coadministration of both drugs in HL rats further delayed PSZ tissue distribution and thus its assumed onset of action and decreased the plasma concentrations of VCR and increased its tissue uptake.It is important to monitor cholesterol and triglyceride levels in ALL patients to avoid aggrevated neurological side effects of VCR and the delay or lack of activity of PSZ.

Introduction {#Sec1}
============

Acute lymphoblastic leukemia (ALL) is a highly malignant disease characterized by immature lymphoid cells in the bone marrow, peripheral blood, and other organs \[[@CR20], [@CR36]\]. Acute lymphoblastic leukemia has a high incidence in USA where it is responsible for approximately 20,000 cancer diagnoses and 10,000 deaths annually \[[@CR11], [@CR36]\]. It has a median diagnosis age of 14 years \[[@CR20]\]. Vincristine (VCR) is an antineoplastic agent that serves as one of the cornerstones in the induction, intensification, and consolidation of ALL treatment phases \[[@CR39]\]. VCR is a key treatment for rhabdomyosarcoma, neuroblastoma, Wilms' tumor, Hodgkin's disease, and non-Hodgkin's lymphomas \[[@CR20], [@CR29]\]. It acts through the inhibition of dividing cells at the metaphase stage, thus VCR may lead to neurological adverse effects \[[@CR14], [@CR19]\]. The dose and the duration of exposure to VCR greatly affect its clinical efficacy as well as its neurological toxicity \[[@CR36]\]. VCR neurotoxicity is dose limiting, characterized by reversible symptoms such as paresthesia, sensory inadequacy, and seizures \[[@CR14], [@CR35]\]. Consequently, the safety and efficacy of VCR may be enormously affected by minor changes in its plasma concentration.

The reported clinical pharmacokinetic data for VCR exhibit a wide variability in the elimination phase half-life (*t* ~1/2~) (range 155--5100 min), volume of distribution (*V* ~d~) (range 57--420 L/m^2^), and clearance (range 82--482 mL/min/m^2^) among tested patients \[[@CR36]\]. VCR demonstrated linear low affinity binding to plasma proteins, mainly AAG, with a reported unbound fraction of 0.5 \[[@CR9]\]. Its short distribution *t* ~1/2~, long elimination *t* ~1/2~, and large *V* ~d~ suggest a decreased tumor tissue exposure in vivo because of its high capability to bind to tissues \[[@CR36]\]. In general, VCR has a considerable tendency to accumulate in most organs and tissues except in fat, eyes, and brain \[[@CR36]\]. Additionally, VCR undergoes metabolism in liver by cytochrome P450 (CYP)3A (mainly CYP3A4 and CYP3A5) and is eliminated mainly in bile with approximately 8--15% excreted in urine \[[@CR9], [@CR14], [@CR36]\]. In rats, VCR has demonstrated a similar pharmacokinetic pattern, exhibiting a biphasic plasma drug concentration decay with a rapid distribution phase *t* ~1/2~ (42--73 min) followed by a slower elimination phase *t* ~1/2~ of 14.3 ± 6.3 h \[[@CR20]\]. VCR also presented a relatively large *V* ~d~ and a clearance of 0.12 ± 0.08 L/h/kg \[[@CR20], [@CR42]\].

Owing to their immunocompromised state and intensive chemotherapy, the ALL patient population is highly susceptible to invasive fungal infections. Triazole antifungals including fluconazole, voriconazole, itraconazole, and posaconazole (PSZ) are among the common measures taken for the prophylaxis and treatment of invasive fungal infections \[[@CR18], [@CR40]\]. Posaconazole is widely used as prophylactic therapy in hematopoietic stem cell transplant recipients with graft-vs.-host disease, or in individuals with hematological malignancies experiencing prolonged neutropenia as a result of intensive chemotherapy \[[@CR3], [@CR18], [@CR22]\].

After oral administration in humans, PSZ is erratically absorbed and follows linear pharmacokinetics. Posaconazole has a large *V* ~d~ (1774 L), and is considerably bound to plasma proteins with a proportion of 98% to albumin \[[@CR18], [@CR22], [@CR25]\]. Posaconazole has a median *t* ~1/2~ between 15 and 35 h \[[@CR7]\]. The time reported to reach maximum plasma concentration is between 6 and 8 h \[[@CR33]\]. Posaconazole is excreted unchanged in feces, with only 16% undergoing glucuronidation through UGT1A4 and recovered in urine \[[@CR10], [@CR18]\]. It was also reported that PSZ undergoes enterohepatic circulation, presenting a second peak after 24 h \[[@CR24], [@CR33]\]. As a CYP3A4 inhibitor, PSZ has higher potential for drug--drug interactions with CYP3A4 substrates \[[@CR18], [@CR23], [@CR25]\]. In rats, PSZ also follows linear pharmacokinetics, its absorption is slow with the maximum plasma concentration reached within 3--12 h in fed rats and an oral bioavailability of 6.7% \[[@CR22]\]. Posaconazole is highly protein bound (97--99%) and demonstrates low clearance values between 0.103 and 0.207 L/h/kg. Enterohepatic recirculation was also reported with the use of PSZ, showing a second peak in rats and mice; however, this was not the case in dogs \[[@CR22], [@CR32]\].

Hyperlipidemia is a chronic disease characterized by high plasma lipoprotein levels \[[@CR5], [@CR16], [@CR41]\]. The risk factors of hyperlipidemia include genetic makeup defects, unhealthy diet, sedentary lifestyle habits, and certain drugs or diseases \[[@CR15]\]. The incidence of hyperlipidemia had remarkably increased in the last few years as a result of the increase in diabetes mellitus and obesity worldwide \[[@CR15], [@CR41]\]. Hyperlipidemia is accompanied by a consistent increase in low-density lipoprotein that is a key contributor to an increased risk of atherosclerosis, hypertension, and ischemic heart disease \[[@CR17], [@CR30]\]. Furthermore, hyperlipidemia was shown to result in alterations in the pharmacokinetic and pharmacodynamics pattern of some drugs \[[@CR1], [@CR16], [@CR22], [@CR34], [@CR37]\]. This may be attributed to reduced unbound fraction, enhanced lipoprotein receptor-mediated drug tissue uptake, and/or altered metabolizing enzyme expression \[[@CR15], [@CR17], [@CR22], [@CR34]\]. Recently, patients who have undergone allogenic hematopoietic stem cell transplantation have shown a high incidence of hyperlipidemia \[[@CR2]\]. In addition, acute and severe hypertriglyceridemia (\>10,000 mg/L of the plasma triglyceride level) was shown to be associated with VCR/L-asparaginase treatment of patients with ALL and malignant lymphoma \[[@CR20], [@CR38]\].

Recent reports have demonstrated that hyperlipidemia resulted in significant changes in PSZ pharmacokinetics and tissue distribution in rodents with hyperlipidemia \[[@CR8], [@CR22]\]. However, it resulted in insignificant alterations in VCR pharmacokinetics and protein binding in rats \[[@CR20]\]. Thus, hyperlipidemia alone may not pose a threat to the VCR clinical efficacy and toxicity \[[@CR20]\]. Recent publications have demonstrated that co-administration of azoles including PSZ with VCR led to an increased VCR toxicity \[[@CR12], [@CR14], [@CR27], [@CR31]\]. Ketoconazole is another azole antifungal whose pharmacokinetic parameters were not affected by hyperlipidemia in rats. However, its liver uptake was altered and the severity of its drug interaction with midazolam was increased \[[@CR16]\]. Whether hyperlipidemia could potentiate or reduce the severity of the drug interaction between PSZ and VCR is still unknown. Therefore, the aim of the current study is to test the impact of different levels of plasma lipoproteins on the disposition of PSZ and VCR regarding their plasma levels, protein binding, and tissue distribution in a polymer-induced hyperlipidemic rat model.

Methodology {#Sec2}
===========

Materials and Reagents {#Sec3}
----------------------

Vincristine and posaconazole powders (purity \>99%) were purchased from Selleckchem (Houston, TX, USA). Itraconazole was a kind gift from Nifty Labs Pvt Ltd (Hyderabad, India). High-performance liquid chromatography grade methanol and acetonitrile (Fisher Scientific UK Limited, Loughborough, UK), analytical grade potassium dihydrogen orthophosphate (Riedel-de-Haën, Germany), and high-purity distilled water were used. Vinracine^®^ intravenous injection vials labeled to contain 1 mg/mL of VCR sulfate (EIMC United Pharmaceuticals, Cairo, Egypt), Aerraine^®^ isoflurane USP, normal saline, and heparin sodium for injection 5000 U/mL were purchased from the Egyptian local market. Noxafil^®^ oral suspension labeled to contain 40 mg/mL of PSZ (Pathe 103 on Inc., ON, Canada) was purchased from Schering-Plough S.A., Alexandria, Egypt.

Animals and Pre-Experimental Procedures {#Sec4}
---------------------------------------

Experimental protocols involving animals were approved by the Ethics Committee of the Faculty of Pharmacy, Alexandria University. Sprague--Dawley rats were used in the studies. All rats weighed between 150 and 250 g and were housed in temperature-controlled rooms with 12 h of light per day. The animals were fed a standard commercial rat chow containing 4.5% fat (Tanta Oil and Soap JSC, Tanta, Egypt). Free access to food and water was permitted prior to experimentation. Rats were allocated into normolipidemic (NL), intermediate hyperlipidemic (IHL), or extreme hyperlipidemic (HL) groups. Hyperlipidemia was induced by a single intraperitoneal injection of 1 g/kg of P407 (0.13 g/mL solution in normal saline). To ensure the proper injection of P407, the animals were lightly anesthetized using isoflurane, and then allowed to recover. The rats were prepared for intravenous dosing by jugular vein cannulation. For each rat, a single jugular vein was catheterized with Silastic Laboratory Tubing (Dow Corning Corporation, Midland, MI, USA) under isoflurane/O~2~ anesthesia. The cannula was filled with locking solution containing 100 U/mL of heparin in 0.9% saline. After implantation, the rats were transferred to their regular holding cages and allowed free access to water, but food was withheld overnight so that the drug would be administered in the fasted state. The next morning, NL rats were transferred to the metabolic cages and dosed with PSZ orally; 4 h later, the rats were given VCR intravenously via the cannulated jugular vein. As for the HL and IHL groups, the dosing was started 36 and 72 h after the P407 injection, respectively \[[@CR6], [@CR22]\].

Drug Administration and Sample Collection {#Sec5}
-----------------------------------------

For the pharmacokinetic study, the rat groups (*n* = 6--10 each) received PSZ 40 mg/kg by oral gavage. Noxafil^®^ oral suspension (40 mg/mL) was used for the administration of PSZ. Four hours later, the rat groups received 0.15 mg/kg VCR intravenously via the jugular vein cannula, immediately followed by an injection of normal saline. The intravenous solution was prepared by diluting the Vinracine^®^ (1 mg/mL) injection vials with normal saline to reach a final concentration of 0.1 mg/mL. At the time of the first sample withdrawal post-intravenous dosing, the first 0.2 mL of blood was discarded. Food was provided to animals 5 h after the dose administration.

Serial blood samples (0.15--0.25 mL) were collected using the jugular vein cannula at 0.5, 1, 1.5, 2, 4.083, 4.25, 4.5, 5, 6, 8, 10, 24, 48, 72, and 96 h after the PSZ oral dose for each group. Plasma was separated by centrifugation of the blood at 4000*g* for 5 min and transferred into clean glass test tubes. The samples were kept at −20 °C until assayed.

Protein-Binding Study {#Sec6}
---------------------

The unbound fractions of PSZ and VCR in plasma were determined using ultrafiltration (Centrifree^®^; Amicon, Beverly, MA, USA). Blood was obtained from NL, IHL, and HL rats by exsanguination via cardiac puncture. For IHL and HL rats, blood was collected 72 and 36 h after intraperitoneal doses of P407, respectively. The blood was centrifuged at 2500*g* for 10 min. The NL, IHL, and HL rat plasma were spiked with PSZ and VCR methanolic solution to allow for final concentrations of 3.5 and 1 mg/L, respectively. The volume of methanol added to each tube did not exceed 0.05% (v/v). Tubes were incubated for 1 h in a 37 °C water bath shaker \[[@CR15], [@CR20]\]. One milliliter of each tube was transferred to an ultrafiltration device (*n* = 4) (Centrifree^®^; Millipore, Carrigtwohill, Ireland), which was then placed in a fixed-angle centrifuge rotor and spun at 2000*g* for 10 min at 37 °C. The samples were then analyzed for PSZ and VCR concentrations. In HL and IHL protein-binding tests, the ultrafiltration devices were pre-incubated with 5% Triton^®^ (X-100) for 12 h to overcome the binding of drugs and lipids to the filter. The devices were then used after being rinsed several times with double-distilled water \[[@CR16], [@CR22]\].

Assay {#Sec7}
-----

A validated high-performance liquid chromatography assay was used for the measurement of PSZ and VCR concentrations, with itraconazole as an internal standard in plasma, Sorenson sodium phosphate buffer (pH 7.4), liver tissue and lung tissues \[[@CR21]\]. The validated lower limit of quantitation was 50 ng/mL based on 0.2 mL of plasma, tissue homogenate, or buffer. For standard curve construction, drug-free plasma, tissue homogenate, and Sorenson sodium phosphate buffer (pH 7.4) were used and spiked with appropriate amounts of PSZ and VCR. The calibration curves relating the peak area ratio to the expected concentration were highly linear from 50 to 5000 ng/mL of PSZ and VCR in NL, IHL, HL plasma, tissue homogenate and buffer (*r* ^2^ \> 0.997).

Data and Statistical Analysis {#Sec8}
-----------------------------

Non-compartmental methods were applied to calculate the pharmacokinetic parameters. The elimination rate constant (*λz*) was calculated by subjecting the plasma concentrations in the terminal phase to linear regression analysis. The terminal phase *t*½ was calculated using the equation *t*½ = 0.693/*λz*. The area under the plasma concentration--time curve from time zero to infinity (AUC~0--∞~) was calculated using the combined log-linear trapezoidal rule from time zero post-dose to the time of the last measured concentration, plus the quotient of the last measured concentration divided by *λz*. The concentration at time zero after intravenous dosing was estimated by back extrapolation of the log-linear regression line using the first three measured plasma concentrations. The clearance was calculated as the quotient of dose to AUC~0--∞~ and the *V* ~d~ as the quotient of clearance by *λz*. The *V* ~d~ of the central compartment is calculated as the quotient of dose by the concentration at time zero. The PSZ maximum plasma concentration and the time at which it occurred were determined by visual examination of the data.

The plasma-unbound fraction was determined by dividing the PSZ or VCR concentration in the filtrate by that measured in the pre-filtered plasma. All compiled data were reported as mean ± standard deviation, unless otherwise indicated. Significance of comparisons of means for the interactions of lipoprotein status, VCR pharmacokinetics, PSZ pharmacokinetics, and protein binding were assessed by two-way analysis of variance (ANOVA), followed by Tukey's multiple comparison post-hoc test (Prism, Irvine, CA, USA). In all cases, the level of significance was set at *p* = 0.05.

Results {#Sec9}
=======

Pharmacokinetics and Protein Binding {#Sec10}
------------------------------------

Upon co-administration of 40 mg/kg of PSZ and 0.15 mg/kg of VCR in NL rats, PSZ showed higher plasma concentrations than VCR at all timepoints (Fig. [1](#Fig1){ref-type="fig"}). Both PSZ and VCR showed few pharmacokinetic alterations compared with when solely administered \[[@CR20], [@CR22]\]. However, PSZ showed a significantly lower unbound fraction (fu = 0.011 ± 0.007), oral clearance (CL/*f*), oral volume of distribution (Vd/f), and *t* ~1/2~ values (Table [1](#Tab1){ref-type="table"}). It also exhibited statistically higher *C* ~max2~ and AUC~0--∞~ (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}) than those previously reported for PSZ when administered alone in NL rats \[[@CR22]\]. Co-administered VCR demonstrated a twofold higher unbound fraction (fu = 0.336 ± 0.022) than that previously reported for VCR when administered alone in NL rats. This was accompanied by a confirmatory trend of decreasing Co by half \[[@CR20]\]. However, the decrease in Co was not statistically significant owing to the high variability between the rats. Moreover, the VCR Vc increased significantly with an increasing trend in the *t* ~1/2~ (Table [2](#Tab2){ref-type="table"}).Fig. 1Comparative mean ± standard deviation plasma concentration vs. time curves of 0.15 µg/kg of vincristine (VCR) co-administered with 40 mg/kg of oral posaconazole (PSZ) in normolipidemic rats Table 1Pharmacokinetic parameters of posaconazole (PSZ) after co-administration of an oral 40-mg/kg suspension and intravenous 0.15 µg/kg of vincristine (VCR) in normolipidemic (NL), intermediate hyperlipidemic (IHL), and extreme hyperlipidemic (HL) ratsNLIHLHL*C* ~max1~ (mg/L)3.93 ± 1.59^a^8.27 ± 3.86^d^7.20 ± 2.82^b^*C* ~max2~ (mg/L)10.8 ± 2.14^a,d^5.00 ± 4.406.76 ± 2.66^b^*T* ~max1~ (h)6.20 ± 2.287.40 ± 2.798.01 ± 1.71^b^*T* ~max2~ (h)45.0 ± 20.058.4 ± 31.9^d^39.2 ± 13.3AUC~0--24h~ (mg h/L)92.7 ± 68.572.5 ± 37.9^c^145.7 ± 54.4AUC~0--∞~ (mg h/ L)13575.5 ± 15787.6^d^6896.3 ± 4063.120836.7 ± 39381.9*λz* (h^−1^)0.0334 ± 0.01630.037 ± 0.0090.06 ± 0.03*t* ~1/2~ (h)26.6 ± 16.1^d^19.4 ± 5.3513.1 ± 4.44CL/f \[L/(h kg)\]0.019 ± 0.0164^d^0.008 ± 0.0070.007 ± 0.005^d^VD/*f* (L/kg)0.233 ± 0.253^d^0.219 ± 0.1540.136 ± 0.0719*AUC* ~*0--24h*~ area under the plasma concentration--time curve from time zero to 24 h, *AUC* ~*0--∞*~ area under the plasma concentration--time curve from time zero to infinity, *CL/f* oral clearance, *C* ~*max*~ maximum plasma concentration, *t* ~*1/2*~ half-life, *T* ~*max*~ time to maximum concentration, *Vd/f* oral volume of distribution, *λz* elimination rate constant^a^Significant difference between NL and IHL rat groups (*p* \< 0.05)^b^Significant difference between NL and HL rat groups (*p* \< 0.05)^c^Significant difference between IHL and HL rat groups (*p* \< 0.05)^d^Significant difference between PSZ alone and co-administration with VCR according to a two-way analysis of variance, followed by Tukey's multiple comparison post-hoc test \[[@CR22]\] Table 2Pharmacokinetic parameters of intravenous 0.15 µg/kg of vincristine (VCR) coadministered with oral 40 mg/kg posaconazole in normolipidemic (NL), intermediate hyperlipidemic (IHL), and extreme hyperlipidemic (HL) ratsNLIHLHLCo (mg/L)0.560 ± 0.5560.643 ± 0.3880.684 ± 0.520AUC~0--24h~ (mg h/L)2.37 ± 0.664^b^2.32 ± 0.36^c,d^0.894 ± 0.372AUC~0--∞~ (mg h/L)8.90 ± 3.50^b^10.1 ± 5.08^c,d^2.36 ± 0.567*λz* (h^−1^)0.03 ± 0.020.04 ± 0.0160.02 ± 0.022*t* ~½~ (h)27.7 ± 15.124.1 ± 11.7^c^50.3 ± 31.8CL/kg (L/h/kg)0.033 ± 0.030.02 ± 0.009^c,d^0.068 ± 0.013*V* ~d~/kg (L/kg)0.701 ± 0.208^b^0.445 ± 0.291^c^4.4 ± 3.63*V* ~c~/kg (L/h/kg)0.423 ± 0.1710.343 ± 0.2280.375 ± 0.350*AUC* ~0--24h~ area under the plasma concentration--time curve from time zero to 24 h, *AUC* ~0--∞~ area under the plasma concentration--time curve from time zero to infinity, *CL* clearance, *Co* plasma concentration at time zero, *t* ~*½*~ half-life, *Vc* volume of distribution of the central compartment, *Vd* volume of distribution, *λz* elimination rate constant^a^Significant difference between NL and IHL rat groups (*p* \< 0.05)^b^Significant difference between NL and HL rat groups (*p* \< 0.05)^c^Significant difference between IHL and HL rat groups (*p* \< 0.05)^d^Significant difference between VCR alone and co-administration with PSZ according to a two-way analysis of variance, followed by Tukey's multiple comparison post-hoc test \[[@CR20]\]

Elevation of the lipoprotein levels in plasma resulted in some alterations in the pharmacokinetic profile of the co-administered PSZ and VCR (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}; Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). For PSZ, increasing the plasma lipoprotein levels demonstrated a significant increase in *C* ~max1~ (NL \< IHL = HL) and AUC~0--24h~ (NL = IHL \< HL) similar to what was previously reported for PSZ administered alone in such rats \[[@CR22]\]. The PSZ unbound fraction in IHL and HL rats could not be measured because it decreased to a level below our analytical assay lower limit of quantification, especially with the presence of an interfering background peak that resulted in false higher concentrations in such groups \[[@CR21]\]. The remainder of the PSZ pharmacokinetic parameters including CL/*f*, *V* ~d~/*f*, and *t* ~1/2~ did not show any change with the elevation of the plasma lipoprotein levels.Fig. 2Comparative mean ± standard deviation plasma concentration vs. time curves of 40 mg/kg of oral posaconazole (PSZ) co-administered with 0.15 mg/kg of vincristine in normolipidemic (NL), intermediate hyperlipidemic (IHL), and extreme hyperlipidemic (HL) rat groups Fig. 3Comparative mean ± standard deviation plasma concentration vs. time curves of 0.15 mg/kg of vincristine (VCR) co-administrated with 40 mg/kg of oral posaconazole in normolipidemic (NL), intermediate hyperlipidemic (IHL), and extreme hyperlipidemic (HL) rat groups

For VCR, increasing the plasma lipoproteins levels was previously reported not to alter VCR pharmacokinetic parameters when administered alone \[[@CR20]\]. However, upon co-administration with PSZ, HL rats showed a significant decrease (\~71%) in AUC~0--24h~ and AUC~0--∞~, accompanied by a significant increase in *V* ~d~/*f*/kg compared with NL rats (Table [2](#Tab2){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). The clearance showed an increasing trend though it was not significant.

Tissue Distribution {#Sec11}
-------------------

Normolipidemic rats co-administered PSZ with VCR showed significantly higher PSZ liver AUC~0--48h~ than those administered PSZ alone (Table [3](#Tab3){ref-type="table"}). However, PSZ lung AUC~0--48h~ was not significantly different between the two rat groups (Table [3](#Tab3){ref-type="table"}) \[[@CR22]\]. Posaconazole liver and lung Kp (rate of tissue uptake calculated by dividing the drug tissue concentrations by drug plasma concentrations) values were also similar between both groups (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR22]\]. Hyperlipidemic rats co-administered PSZ and VCR showed significantly lower PSZ uptake for the first 8 h with a delayed appearance of *C* ~max~ (\~24 h) in liver and lung tissues (Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}). However, PSZ liver and lung AUC~0--48h~ were significantly higher in HL rat groups (Table [3](#Tab3){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}).Table 3Area under the concentration--time curve (mean ± standard deviation) of posaconazole (PSZ) in normal (NL) and hyperlipidemic (HL) rats after oral administration of 40 mg/kg alone and after co-administration of 0.15 mg/kg of vincristine (VCR) in tissue distribution study using the bailer methodNL AUC~0--48h~HL AUC~0--48h~PSZPSZ + VCRPSZPSZ + VCRPlasma (mg h/L)68.10 ± 9.43^b^171.2 ± 17.7^a^343.7 ± 141.3325.9 ± 61.9Liver (mg h/kg)253.0 ± 20.9^b^480.5 ± 66.5^a^267.5 ± 47.5^b^653.2 ± 56.2Lung (mg h/kg)50.50 ± 5.8346.03 ± 9.46^a^51.02 ± 8.18^b^132.3 ± 7.78*AUC* ~*0--48h*~ area under the plasma concentration--time curve from time zero to 48 h^a^Significant difference between NL and HL rat groups (*p* \< 0.05)^b^Significant difference between PSZ and PSZ + VCR rat groups within the same lipidemic group (*p* \< 0.05) \[[@CR22]\] Fig. 4Mean ± standard deviation liver or lung to plasma ratios of posaconazole (PSZ) vs. time curves in normolipidemic (NL) and hyperlipidemic (HL) rats after 40 mg/kg of oral PSZ, which was co-administered with 0.15 mg/kg of intravenous vincristine 4 h later (*n* = 4 rats at each timepoint). *Asterisk* indicates statistical significance, *p* \< 0.05 Fig. 5Comparative mean ± standard deviation liver and lung concentration vs. time curves of 40 mg/kg of oral posaconazole (PSZ) after co-administration with 0.15 mg/kg of intravenous vincristine 4 h later in normolipidemic (NL) and extreme hyperlipidemic (HL) rat groups

Co-administered VCR showed a significantly higher tissue, liver, and lung uptake in HL rats along all tested points (Fig. [6](#Fig6){ref-type="fig"}). VCR liver and lung AUC~0--48h~ were significantly higher in HL rats (Table [4](#Tab4){ref-type="table"}; Fig. [7](#Fig7){ref-type="fig"}). The *C* ~max~ for tissue was achieved relatively faster than that of PSZ (Figs. [5](#Fig5){ref-type="fig"}, [7](#Fig7){ref-type="fig"}).Fig. 6Mean ± standard deviation liver/lung to plasma ratios of vincristine (VCR) vs. time curves in normolipidemic (NL) and hyperlipidemic (HL) rats after 40 mg/kg of oral posaconazole, which was co-administered with 0.15 mg/kg of intravenous VCR 4 h later (*n* = 4 rats at each timepoint). *Asterisk* indicates statistical significance, *p* \< 0.05 Table 4Area under the plasma concentration--time curve (mean ± standard deviation) of vincristine (VCR) in normal (NL) and hyperlipidemic (HL) rats after oral administration of 40 mg/kg of posaconazole followed by 0.15 mg/kg of VCR intravenously 4 h later in the tissue distribution study using the bailer methodVCR AUC~0--48h~NLHLPlasma (mg h/L)1.53 ± 0.191.94 ± 0.19Liver (mg h/kg)5.73 ± 0.89^a^48.90 ± 13.8Lung (mg h/kg)4.38 ± 2.14^a^23.61 ± 7.95*AUC* ~*0***--***48h*~ area under the plasma concentration--time curve from time zero to 48 h^a^Significant difference between NL and HL rat groups (*p* \< 0.05) Fig. 7Comparative mean ± standard deviation liver and lung concentration vs. time curves of 0.15 mg/kg of intravenous vincristine (VCR) 4 h after 40 mg/kg of oral posaconazole in normolipidemic (NL) and extreme hyperlipidemic (HL) rat groups

Discussion {#Sec12}
==========

The study demonstrates that hyperlipidemia augments the drug interaction between PSZ and VCR. It results in a delayed PSZ tissue penetration. However, it decreases VCR plasma availability and increases its tissue penetration. This finding raises the possibility that patients with ALL with elevated lipoprotein levels co-administered both drugs are prone to a decreased VCR efficacy accompanied by more side effects, in addition to lower PSZ antifungal activity against invasive fungal infections.

Posaconazole co-administration with VCR was reported to increase the latter side effects, mainly peripheral neuropathy. A few case reports have also demonstrated VCR central toxicity, leading to seizures in ALL patients \[[@CR14], [@CR26], [@CR28]\]. This was generally interpreted by the PSZ inhibition of CYP3A4, thus decreasing VCR clearance and increasing the latter side effects \[[@CR14]\]. In our current model and study design, we suggest other resolutions as well. To study the effect of hyperlipidemia using our rat model, we gave the PSZ as a single dose followed by VCR 4 h later after PSZ reaches its *C* ~max~. Thus, CYP3A4 inhibition may not be fully attained by PSZ. Instead, it is proven that both PSZ and VCR are excreted through the bile and undergo enterohepatic recirculation \[[@CR20], [@CR22]\]. This was clearly shown in this study also, where the two drugs demonstrated two peaks on the plasma concentration--time curve of each drug upon co-administration (Fig. [1](#Fig1){ref-type="fig"}). Moreover, our results show that co-administration of both drugs in NL rats leads to significantly higher PSZ liver concentrations and AUC~0--48~ than in the NL rats administered PSZ alone (Table [3](#Tab3){ref-type="table"}) \[[@CR22]\]. This was not the case for PSZ lung concentrations, indicating potential competition with VCR on bile elimination rather than an effect on tissue uptake. This was accompanied by a significant decrease in PSZ CL/*f* and an increase in AUC~0--∞~ as well as *C* ~max2~ (Table [1](#Tab1){ref-type="table"}) in NL rats co-administered both drugs compared with those administered PSZ alone \[[@CR22]\]. On the other hand, VCR has shown an increased unbound fraction and higher *V* ~c~ and a trend of a prolonged half-life in co-administered NL rat groups \[[@CR20]\].

Posaconazole prophylactic therapy against invasive *Aspergillus* and *Candida* infections in patients with ALL has shown mortality benefits as well as better outcomes towards invasive fungal infections refractory to itraconazole therapy \[[@CR18]\]. Posaconazole has greater and faster lung penetration than other azole antifungal treatments \[[@CR13]\]. It was previously proven that hyperlipidemia altered PSZ liver and lung distribution, resulting in a delayed onset and decreased magnitude of its activity and/or drug-interaction pattern \[[@CR22]\]. In the current study, hyperlipidemia affected co-administered PSZ in the same manner, resulting in a greater delay in its onset of action and/or interaction in the lung and/or liver. However, co-administered PSZ demonstrated higher lung and liver concentrations in HL rats than in NL rats and higher uptake after 24 h, which was accompanied by lower plasma *C* ~max2~. The delayed onset of action of PSZ in the lung as well as the higher tissue concentrations of PSZ in HL rats upon co-administration with VCR could be attributed to the combined effect of the competitive inhibition between both drugs on efflux and influx proteins. In addition to the effect of hyperlipidemia reported previously to downregulate the expression and/or the functional activity of (MDR1) P-glycoprotein and other efflux proteins \[[@CR4], [@CR22]\]. In fact, hyperlipidemia alone and VCR co-administration alone did not alter the PSZ AUC~0--48h~ in lung tissues. Whereas, the AUC~0--48h~ of PSZ in lungs of HL rats that were co-administered VCR increased \~2.5 fold (Table [3](#Tab3){ref-type="table"}). Looking at the liver tissues, co-administration with VCR increased the PSZ AUC~0--48h~ by 1.9-fold in NL rats. Whereas, hyperlipidemia alone showed a trend of increasing PSZ AUC~0--48h~ that was not statistically significant. Upon combining both factors, the AUC~0--48h~ value increased 2.5-fold (Table [3](#Tab3){ref-type="table"}). This necessitates further investigation into the efflux and influx proteins responsible for PSZ and VCR in the future to determine the effect of hyperlipidemia on these proteins and to describe in detail the molecular mechanisms involved in such drug interactions.

Although no effect was detected previously for the increased lipoprotein levels on VCR pharmacokinetics and protein binding, HL rats co-administered VCR and PSZ showed significantly lower VCR AUC~0--24h~ and AUC~0--∞~ accompanied by a significant increase in *V* ~d~/*f*/kg compared with NL rats. This was not attributed to the initial dose for such group where the concentration at time zero values among the different lipidemic groups were consistent. In addition, VCR liver and lung uptake and concentrations were consistently higher in HL rats than NL rats. Thus, HL accompanied by PSZ co-administration results in decreased VCR plasma availability and increased tissue distribution. This may result in lower efficacy for anticancer drugs and increased side effects.

Conclusion {#Sec13}
==========

Hyperlipidemia in rat resulted in alterations in PK of PSZ and delayed onset of activity and decreased tissue uptake. Whereas, HL by itself did not alter the PK of VCR. Upon coadministration, PSZ showed significantly lower Cl/F and significantly higher AUC and liver concentrations but unchanged lung concentrations. Whereas, VCR showed larger unbound fraction and volume of distribution. Coadministration associated with elevation in plasma lipoproteins resulted in further delay in PSZ tissue distribution however, a total higher liver and lung AUC~0-48~. On the other hand, it resulted in decreased VCR plasma availability and increased its tissue uptake and concentration. Thus as a conclusion, monitoring the cholesterol and triglyceride levels in ALL patients is advisable to avoid the aggravated neurological side effects of VCR and the lack or delay of activity of both PSZ and VCR.
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